Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
Sachem Head Capital Management reportedly wants Shire to offload or spin-off some of its assets as it grows frustrated with the falling share price
CS analysts say AstraZeneca is finally starting to get over the patent expiries of several blockbuster drugs, including Crestor, Seroquel and Nexium
"The Breakthrough Therapy Designation acknowledges not only Tagrisso's potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease”
“Assuming that the application is approved by the High Court, the joint administrators will subsequently take steps to return control of the company to the directors, following which the directors will seek to lift the suspension of the company's ordinary shares”
The further subscription has been announced to accommodate an investor who wasn’t able to get the necessary paperwork completed to take part in last week’s fundraising
“It is really pleasing to receive this notification of allowance for this latest VAL401 patent so close on the heels after our encouraging and positive announcement of first verified clinical data emerging from the VAL401 trial
It was a busy few days at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Greece last week
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now